Hydroxychloroquine, Pentoxifylline, and Colchicine: Off-Label is ON in Dermatology
So many diseases, so few FDA approved indications. Between the mind-numbing time and cost from bench to bottle, it is no surprise that dermatologists, as masters of the integument are the off-label bandits, marrying their wealth of knowledge on the pathophysiology of skin diseases to the mechanisms by which medications work to create an evidenced-based armament of therapies for both common and rar …
So many diseases, so few FDA approved indications. Between the mind-numbing time and cost from bench to bottle, it is no surprise that dermatologists, as masters of the integument are the off-label bandits, marrying their wealth of knowledge on the pathophysiology of skin diseases to the mechanisms by which medications work to create an evidenced-based armament of therapies for both common and rar … 
Each month the JDD Dermatology Podcast discusses a current issue in dermatology and this December Dr. Adam Friedman sat down with Dr. Gideon Smith, assistant professor of dermatology at Harvard Medical school, Vice Chair for Clinical Affairs in Dermatology, and Director of the Connective Tissue Diseases Clinic and Fellowship to discuss pruritus in the autoimmune connective tissue world.
Dr. … 
Just as systemic lupus erythematosus (LE) can have protean systemic manifestations, cutaneous LE can present in many different ways. When confronted with the many faces of mucocutaneous LE, the following pearls can be valuable.
1. Be Aware of the SLICC Criteria
In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) developed a set of clinical and immunologic criteria to assist … 